Drugs / VX-668
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05727800 | Feb → Sep 2023 | alpha 1-antitrypsin deficiency | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05727800 ↗ |
| Route | Oral | “Suspension for oral administration.” NCT05727800 ↗ |